Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.

@article{Chapple2007DarifenacinTO,
  title={Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial.},
  author={Christopher R Chapple and Catherine E Dubeau and Ursula Ebinger and Ludmyla Rekeda and Andrea Viegas},
  journal={Current medical research and opinion},
  year={2007},
  volume={23 10},
  pages={2347-58}
}
BACKGROUND Overactive bladder (OAB) increases in prevalence with advancing age. This study specifically investigated patients >or= 65 years, evaluating the efficacy, tolerability, safety and quality of life (QoL) outcomes from darifenacin treatment. METHODS Patients (n = 400, mean age 72 years) with OAB were randomized (2:1) to receive 12 weeks of double-blind treatment with darifenacin (7.5 mg once daily for 2 weeks, then optional titration to 15 mg daily) or placebo (with sham titration… CONTINUE READING
46 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

Similar Papers

Loading similar papers…